CANNANNEW REPORT

Christian Angermayer•  bei Apeiron Investment Group ATAI Life Sciences AG (NASDAQ: ATAI), the innovative mental health platform company I have started in 2018 and which is committed to unlocking the compelling potential of psychedelics, has announced this morning that it has bought an additional stake in COMPASS Pathways (NASDAQ: CMPS), bringing atai's ownership in Compass beyond 20%. Learn more about our reasons and considerations. In short: IMO COMPASS Pathway is one of the most undervalued & impactful biotech stocks out there – and atai is committed to being the global leader in novel mental health treatments. Our reasons to increase our stake in COMPASS Pathways Published on November 30, 2021 atai increases its ownership in Compass Pathways Christian Angermayer Founder bei Apeiron Investment Group 18 articles atai Life Sciences (NASDAQ: ATAI), the innovative mental health platform company I have started in 2018, of which I am Chairman and which is committed to unlocking the compelling potential of psychedelics, has announced this morning that it has bought an additional stake in COMPASS Pathways (NASDAQ: CMPS), bringing atai's ownership in Compass beyond 20%. Here are some of our reasons and considerations: COMPASS Phase 2b results for TRD have been excellent We think the COMPASS Phase 2b trial for Treatment-Resistant Depression (TRD) is a total game-changer. COMPASS had the tenacity to stage the world's largest psilocybin (the active ingredient in so called "magic mushrooms") trial to date – through the pandemic! – and their COMP360 psilocybin candidate has delivered, showing real and meaningful potential in tackling TRD – a major mental health challenge. Treatment-resistant depression – meaning patients have tried everything possible and did not find relief – is a harrowing condition affecting one in three people with depression – that's a staggering one hundred million people worldwide for whom current depression treatments just don't work. In this trial, many patients found…

Excerpt only ...
READ MORE BELOW
Source : Angermeyer Announces That ATAI Have Bought Another Chunk Of Compass Pathways

reposted by Cannabis News World